Nuclear receptors and metabolism: From feast to famine

Diabetologia

Volumn 57, Issue 5, 2014, Pages 860-867

  Hong, Suk Hyun ^a   Ahmadian, Maryam ^a   Yu, Ruth T ^a   Atkins, Annette R ^a   Downes, Michael ^a   Evans, Ronald M ^a,b  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Circadian metabolism; FGFs; Glucose homeostasis; Nuclear receptors; Review

Indexed keywords

CELL NUCLEUS RECEPTOR; FIBROBLAST GROWTH FACTOR; NUCLEAR HORMONE RECEPTOR; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; CELL RECEPTOR; GLUCOSE; LIGAND;

ADIPOSE TISSUE; CIRCADIAN RHYTHM; DIET RESTRICTION; HUMAN; HUNGER; LIVER; METABOLIC REGULATION; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; HOMEOSTASIS; METABOLISM; MUSCLE; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; CIRCADIAN RHYTHM; FASTING; FIBROBLAST GROWTH FACTORS; GLUCOSE; HOMEOSTASIS; HUMANS; LIGANDS; LIVER; MODELS, BIOLOGICAL; MUSCLES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES;

EID: 84898599981     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3209-9     Document Type: Review

References (83)

1. Chambon P (2005) The nuclear receptor superfamily: a personal retrospect on the first two decades. Mol Endocrinol 19:1418-1428 (Pubitemid 41002973)
2. Mangelsdorf DJ, Thummel C, Beato M et al (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839 (Pubitemid 26006525)
3. Privalsky ML (2004) The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66:315-360 (Pubitemid 40614447)
4. Chen H, Tini M, Evans RM (2001) HATs on and beyond chromatin. Curr Opin Cell Biol 13:218-224 (Pubitemid 32209223)
5. Nagy L, Kao HY, Love JD et al (1999) Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev 13:3209-3216 (Pubitemid 30030443)
6. Kapoor A, Goldberg MS, Cumberland LK et al (2010) The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468:1105-1109
7. Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10:355-361 (Pubitemid 38508511)
8. Ahmadian M, Duncan RE, Jaworski K, Sarkadi-Nagy E, Sul HS (2007) Triacylglycerol metabolism in adipose tissue. Future Lipidol 2:229-237 (Pubitemid 46812939)
9. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem 77:289-312
10. Forman BM, Chen J, Evans RM (1996) The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 804:266-275 (Pubitemid 27056615)
11. Barak Y, Nelson MC, Ong ES et al (1999) PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595 (Pubitemid 29531138)
12. Imai T, Takakuwa R, Marchand S et al (2004) Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci U S A 101:4543-4547 (Pubitemid 38437447)
13. He W, Barak Y, Hevener A et al (2003) Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100:15712-15717 (Pubitemid 38021055)
14. Wang F, Mullican SE, DiSpirito JR, Peed LC, Lazar MA (2013) Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ. Proc Natl Acad Sci U S A 110:18656-18661
15. Kershaw EE, Schupp M, Guan HP, Gardner NP, Lazar MA, Flier JS (2007) PPARγ regulates adipose triglyceride lipase in adipocytes in vitro and in vivo. Am J Physiol Endocrinol Metab 293:E1736-E1745 (Pubitemid 350255127)
16. Rodriguez-Cuenca S, Carobbio S, Velagapudi VR et al (2012) Peroxisome proliferator-activated receptor γ-dependent regulation of lipolytic nodes and metabolic flexibility. Mol Cell Biol 32:1555-1565
17. Hollenberg AN, Susulic VS, Madura JP et al (1997) Functional antagonism between CCAAT/Enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter. J Biol Chem 272:5283-5290 (Pubitemid 27090091)
18. Iwaki M, Matsuda M, Maeda N et al (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663 (Pubitemid 36792453)
19. Hofmann C, Lorenz K, Braithwaite SS et al (1994) Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134:264-270 (Pubitemid 24021997)
20. Tomaru T, Steger DJ, Lefterova MI, Schupp M, Lazar MA (2009) Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor γ and CCAAT/enhancer-binding proteins. J Biol Chem 284:6116-6125
21. Agarwal AK, Garg A (2002) A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408-411 (Pubitemid 34084723)
22. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T (2002) PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51:3586-3590 (Pubitemid 35403468)
23. Savage DB, Tan GD, Acerini CL et al (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 52:910-917 (Pubitemid 36384259)
24. Sugii S, Olson P, Sears DD et al (2009) PPARγ activation in adipocytes is sufficient for systemic insulin sensitization. Proc Natl Acad Sci U S A 106:22504-22509
25. Ahmadian M, Suh JM, Hah N et al (2013) PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 19:557-566
26. Rhee J, Inoue Y, Yoon JC et al (2003) Regulation of hepatic fasting response by PPARγ coactivator-1α (PGC-1): requirement for hepatocyte nuclear factor 4α in gluconeogenesis. Proc Natl Acad Sci U S A 100:4012-4017 (Pubitemid 36418148)
27. Kim DK, Gang GT, Ryu D et al (2013) Inverse agonist of nuclear receptor ERRγ mediates antidiabetic effect through inhibition of hepatic gluconeogenesis. Diabetes 62:3093-3102
28. Muoio DM, MacLean PS, Lang DB et al (2002) Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR δ. J Biol Chem 277:26089-26097 (Pubitemid 34967092)
29. Leone TC, Weinheimer CJ, Kelly DP (1999) A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 96:7473-7478 (Pubitemid 29299686)
30. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103:1489-1498
31. Chakravarthy MV, Lodhi IJ, Yin L et al (2009) Identification of a physiologically relevant endogenous ligand for PPARα in liver. Cell 138:476-488
32. Laffitte BA, Chao LC, Li J et al (2003) Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 100:5419-5424 (Pubitemid 36542720)
33. Zhang Y, Lee FY, Barrera G et al (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103:1006-1011 (Pubitemid 43212212)
34. Grefhorst A, Elzinga BM, Voshol PJ et al (2002) Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277:34182-34190
35. Burri L, Thoresen GH, Berge RK (2010) The role of PPARα activation in liver and muscle. PPAR Res. doi: 10.1155/2010/542359
36. Fluck M, Hoppeler H (2003) Molecular basis of skeletal muscle plasticity - from gene to form and function. Rev Physiol Biochem Pharmacol 146:159-216
37. Pette D, Staron RS (2000) Myosin isoforms, muscle fiber types, and transitions. Microsc Res Tech 50:500-509
38. Wu P, Peters JM, Harris RA (2001) Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor α. Biochem Biophys Res Commun 287:391-396 (Pubitemid 32917610)
39. Chao LC, Zhang Z, Pei L, Saito T, Tontonoz P, Pilch PF (2007) Nur77 coordinately regulates expression of genes linked to glucose metabolism in skeletal muscle. Mol Endocrinol 21:2152-2163 (Pubitemid 47347379)
40. Finck BN, Bernal-Mizrachi C, Han DH et al (2005) A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes. Cell Metab 1:133-144 (Pubitemid 43960595)
41. Narkar VA, Downes M, Yu RT et al (2008) AMPK and PPARδ agonists are exercise mimetics. Cell 134:405-415
42. Wang YX, Zhang CL, Yu RT et al (2004) Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol 2:e294 (Pubitemid 39532914)
43. Schuler M, Ali F, Chambon C et al (2006) PGC1α expression is controlled in skeletal muscles by PPARβ, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab 4:407-414 (Pubitemid 44645068)
44. Tanaka T, Yamamoto J, Iwasaki S et al (2003) Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 100:15924-15929 (Pubitemid 38021091)
45. Narkar VA, Fan W, Downes M et al (2011) Exercise and PGC-1α- independent synchronization of type I muscle metabolism and vasculature by ERRγ. Cell Metab 13:283-293
46. Egan B, Zierath JR (2013) Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 17:162-184
47. Guillaumond F, Dardente H, Giguere V, Cermakian N (2005) Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythm 20:391-403 (Pubitemid 41318436)
48. Sato TK, Panda S, Miraglia LJ et al (2004) A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron 43:527-537 (Pubitemid 39094679)
49. Cho H, Zhao X, Hatori M et al (2012) Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature 485:123-127
50. Yin L, Wu N, Curtin JC et al (2007) Rev-erbα, a heme sensor that coordinates metabolic and circadian pathways. Science 318:1786-1789 (Pubitemid 350274391)
51. Raghuram S, Stayrook KR, Huang P et al (2007) Identification of heme as the ligand for the orphan nuclear receptors REV-ERBα and REV-ERBβ. Nat Struct Mol Biol 14:1207-1213 (Pubitemid 350223341)
52. Bugge A, Feng D, Everett LJ et al (2012) Rev-erbalpha and Rev-erbβ coordinately protect the circadian clock and normal metabolic function. Genes Dev 26:657-667
53. Lamia KA, Papp SJ, Yu RT et al (2011) Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature 480:552-556
54. Gachon F, Leuenberger N, Claudel T et al (2011) Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor α (PPARα) activity. Proc Natl Acad Sci U S A 108:4794-4799
55. Yang X, Downes M, Yu RT et al (2006) Nuclear receptor expression links the circadian clock to metabolism. Cell 126:801-810 (Pubitemid 44233631)
56. Angelin B, Larsson TE, Rudling M (2012) Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metab 16:693-705
57. Goetz R, Mohammadi M (2013) Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 14:166-180
58. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235-253
59. Ding X, Boney-Montoya J, Owen BM et al (2012) βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 16:387-393
60. Tomlinson E, Fu L, John L et al (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741-1747 (Pubitemid 34415889)
61. Fu L, John LM, Adams SH et al (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145:2594-2603 (Pubitemid 38686202)
62. Kir S, Beddow SA, Samuel VT et al (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621-1624
63. Kir S, Kliewer SA, Mangelsdorf DJ (2011) Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol 76:139-144
64. Potthoff MJ, Boney-Montoya J, Choi M et al (2011) FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab 13:729-738
65. Ho HK, Pok S, Streit S et al (2009) Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and α-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50:118-127
66. Nicholes K, Guillet S, Tomlinson E et al (2002) A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160:2295-2307 (Pubitemid 34663420)
67. Dutchak PA, Katafuchi T, Bookout AL et al (2012) Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148:556-567
68. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426-437 (Pubitemid 46825495)
69. Inagaki T, Dutchak P, Zhao G et al (2007) Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425 (Pubitemid 46825496)
70. Xu J, Lloyd DJ, Hale C et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-259
71. Kharitonenkov A, Wroblewski VJ, Koester A et al (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774-781 (Pubitemid 46143178)
72. Emanuelli B, Vienberg SG, Smyth G et al (2014) Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest 124:515-527
73. Lin Z, Tian H, Lam KS et al (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17:779-789
74. Holland WL, Adams AC, Brozinick JT et al (2013) An FGF21-adiponectin- ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 17:790-797
75. Bookout AL, de Groot MH, Owen BM et al (2013) FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19:1147-1152
76. Owen BM, Bookout AL, Ding X et al (2013) FGF21 contributes to neuroendocrine control of female reproduction. Nat Med 19:1153-1156
77. Jonker JW, Suh JM, Atkins AR et al (2012) A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485:391-394
78. Gaich G, Chien JY, Fu H et al (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333-340
79. Reitman ML (2013) FGF21 mimetic shows therapeutic promise. Cell Metab 18:307-309
80. Wei W, Dutchak PA, Wang X et al (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 109:3143-3148
81. Wu AL, Kolumam G, Stawicki S et al (2011) Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Trans Med 3:113-126
82. Woldt E, Sebti Y, Solt LA et al (2013) Rev-erb-alpha modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med 19:1039-1046
83. Solt LA, Wang Y, Banerjee S et al (2012) Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485:62-68